Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology
about
The current and future role of magnetic resonance imaging in prostate cancer detection and managementMultiparametric prostate magnetic resonance imaging in the evaluation of prostate cancerTargeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive TechnologyCurrent role of multiparametric magnetic resonance imaging in the management of prostate cancerIntegration of multiparametric MRI into active surveillance of prostate cancer.Personalized prostate cancer screening among men with high risk genetic predisposition- study protocol for a prospective cohort study.Risk stratification of prostate cancer in the modern era.Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.Expectant management for men with early stage prostate cancer.Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls.Clinical and multiparametric MRI signatures of granulomatous prostatitis.Prostate cancer risk stratification with magnetic resonance imaging.Optimizing safety and accuracy of prostate biopsy.High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.The utility of quantitative ADC values for differentiating high-risk from low-risk prostate cancer: a systematic review and meta-analysis.Co-registration of MRI and ultrasound: accuracy of targeting based on radiology-pathology correlationNovel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial).The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy.Serum lipid profiles and aggressive prostate cancerApplication of ultrasound imaging biomarkers (HistoScanning™) improves staging reliability of prostate biopsies.Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer.Molecular imaging and fusion targeted biopsy of the prostate.Targeted Prostate Biopsy in the Era of Active Surveillance.Molecular Signature to Risk-Stratify Prostate Cancer of Intermediate Risk.[Multiparametric MRI and MRI-TRUS fusion biopsy in patients with prior negative prostate biopsy].Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy.Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest.Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?Risk of upgrading from prostate biopsy to radical prostatectomy pathology: Is magnetic resonance imaging-guided biopsy more accurate?
P2860
Q26773645-80FCDBC0-F851-4E57-B56E-0C3150A45BBDQ26776478-FD4132E1-DC22-40E6-B937-7A15BE89B586Q27008215-F655C63C-788E-454C-9117-D3CE077B3913Q28082035-9B2BA3DC-1D1C-4CD7-B8DC-D3232AA910D8Q30249514-FF50A38A-3DB0-4A1B-82E7-0A750AC13727Q30597063-B3A06850-1D7B-427E-86AA-FE619270F891Q35680101-932C7872-0961-40EF-A272-6D746F74DF28Q36649765-8D8A3C9B-C9E8-4459-98DD-55B4667F9E47Q38469754-21BACDD3-D153-4892-AF2A-ADE47EC708F6Q38664945-37BD13C4-3A0F-4C4C-BD41-98E25138D588Q38753165-98C37524-88B0-4193-AF1D-56604700DF62Q38796980-AA3FBFE2-46C4-4E1B-BD13-7BB789E6B7E9Q38841864-B76BDF41-CC01-47E6-9226-03F83E189BD0Q38906488-31C80416-8A45-4249-8B63-6F8AC4CB7029Q38937545-4F5E0DA2-F296-4527-888E-E1649BE6600CQ39446394-32749DE7-6283-42CF-80F6-77DA649F0E0DQ40441625-B195D708-8703-45EF-B5FA-487758221211Q41715814-C7B7B87A-41B9-498A-A41A-D5038E30FEECQ42054281-BD7775F7-C055-4950-8942-234730F2346BQ44135135-E06CC6DF-D7FA-4062-B569-99CF504B0B8FQ44607269-9B7B8AEC-2FF0-4FEE-9D70-F3133150F36DQ47608215-2CE32738-0049-45A4-AB77-BF8181B746B4Q48527660-94F2E84D-408D-4F99-B1EB-F54C6AD02F77Q49210391-11591A54-01E5-4570-8980-0D8317456539Q52983024-4EE24FB6-111F-4F5A-9620-5608DB023147Q53100573-F9C2F92F-786B-42DF-9AF5-33795D237CC2Q53504232-EBDC3D41-1009-438E-A2CC-C8223ED19BC0Q53630425-C6B20E1F-F1CF-482E-A938-8976308F0A10Q57493779-5D252FE4-A682-4B62-A2D9-98BD4000F17A
P2860
Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Magnetic resonance imaging-ult ...... on of final prostate pathology
@ast
Magnetic resonance imaging-ult ...... on of final prostate pathology
@en
Magnetic resonance imaging-ult ...... on of final prostate pathology
@nl
type
label
Magnetic resonance imaging-ult ...... on of final prostate pathology
@ast
Magnetic resonance imaging-ult ...... on of final prostate pathology
@en
Magnetic resonance imaging-ult ...... on of final prostate pathology
@nl
prefLabel
Magnetic resonance imaging-ult ...... on of final prostate pathology
@ast
Magnetic resonance imaging-ult ...... on of final prostate pathology
@en
Magnetic resonance imaging-ult ...... on of final prostate pathology
@nl
P2093
P2860
P1476
Magnetic resonance imaging-ult ...... on of final prostate pathology
@en
P2093
Daniel J A Margolis
David Y Lu
Frederick J Dorey
Geoffrey A Sonn
Jesse D Le
Jiaoti Huang
Leonard S Marks
Michelle Brugger
Patricia Lieu
Robert E Reiter
P2860
P304
P356
10.1016/J.JURO.2014.04.094
P407
P577
2014-05-01T00:00:00Z